Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Slovenia

Slovenia Articles

Industry

BMI View: Krka has posted moderate revenue growth for H112, in line with its expectations for the year. Operating profit and reported profit were down, with higher distribution expenses... 2012-08-03


Industry

BMI View: Our view that Slovenia's drug market is one of the most stable in the region remains in place despite the fact that at the start of 2012 the government introduced new measures... 2012-04-16


Industry

BMI View: Krka's dual listing on the Warsaw Stock Exchange (WSE) will improve the liquidity of the stock by increasing its international exposure and visibility to investors, both of... 2012-04-10


More ARTICLES

Industry

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05


Industry

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2012-03-12


Industry

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2011-11-02


Industry

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12


Industry

BMI View: Our equity view of Slovenian company Krka remains neutral, but with some upside potential since our previous analysis. Despite the company's exposure to high-growth pharmaceutical... 2011-07-08

Emerging Europe InsightEmerging Europe Channels Emerging Europe Countries